AstraZeneca Pharma India Limited reports 30% growth in Q2 FY26-27 with INR 7,291 Mn revenue, driven by strong commercial performance.
AstraZeneca Pharma India Limited (ASTRAZEN) reports 30% revenue growth in Q1 FY2026-27, reaching INR 6,828 Mn, driven by strong portfolio and strategic partn.